Mergers & Acquisitions
By The Online Investor Staff, updated Wed., Feb. 26, 4:50 PM
Slide #25. Eli Lilly and Company — Dermira, Inc.
| Acquirer: |
Eli Lilly and Company (LLY) |
| Acquiree: |
Dermira, Inc. (DERM) |
| Details: |
Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Dermira, Inc. (NASDAQ: DERM). The acquisition expands Lilly's immunology pipeline with the addition of lebrikizumab, a novel, investigational, monoclonal antibody designed to bind IL-13 with high affinity that is being evaluated in a Phase 3 clinical development program for the treatment of moderate-to-severe atopic dermatitis in adolescent and adult patients, ages 12 years and older. The acquisition of Dermira also expands Lilly's portfolio of marketed dermatology medicines with the addition of QBREXZA (glycopyrronium), a medicated cloth approved by the FDA for the topical treatment of primary axillary hyperhidrosis (uncontrolled excessive underarm sweating). |
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.
Eli Lilly SEC Filing Email Alerts Service
Open the LLY Page at The Online Investor »
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. Co.'s diabetes and other endocrinology products include: Baqsimi® and Basaglar®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta® and Emgality®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux® and Verzenio®. Co.'s other products include: Cialis®.
Eli Lilly SEC Filing Email Alerts Service
Open the DERM Page at The Online Investor »
| Company Name: |
| Lilly (Eli) & Co |
| Stock buyback: |
| LLY buyback |
| Website: |
| www.lilly.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding LLY: |
| 105 |
| Total Market Value Held by ETFs: |
| $10.63B |
| Total Market Capitalization: |
| $132.64B |
| % of Market Cap. Held by ETFs: |
| 8.02% |
|
| Company Name: |
| Dermira Inc |
| Website: |
| www.dermira.com |
| Sector: |
| Drugs & Pharmaceuticals |
| Number of ETFs Holding DERM: |
| 22 |
| Total Market Value Held by ETFs: |
| $81.94M |
| Total Market Capitalization: |
| $1.02B |
| % of Market Cap. Held by ETFs: |
| 8.02% |
|
Quotes delayed 20 minutes
|
